Overall, targeting HSP47 offers promising avenues for therapeutic development in atherosclerosis treatment, warranting further exploration to solidify its role as a critical target in reducing the burden of atherosclerotic disease [4,37,53,54]. Here, SERPINH1 is linked to atherosclerosis.